




FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: HOGAN-04448		Serial No.: 09/613,887		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))				Applicant: Kirk Hogan				
				Filing Date: July 11, 2000		Group Art Unit: 1634		
U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date	
QJ		5,413,907	05/09/1995	Ronald G. Worton, <i>et al.</i>	435	6	09/21/1990	
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS								
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
QJ		WO 99/44062	02/09/1999	PCT				
		WO 02/006536	01/24/2002	PCT Search Report				
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)								
QJ ↓	1	Schorge <i>et al.</i> , <i>The Journal of Reproductive Medicine</i> 44: 669-673. [1999] Clinically Significant Venous Thromboembolism After Gynecologic Surgery						
	2	Fritze <i>et al.</i> , <i>Biol. Chem. Hoppe-Seyler</i> 368: 295-298. [1987] Horizontal Two-Dimensional Electrophoresis of Plasma Butyrylcholinesterase						
	3	Tanaka <i>et al.</i> , <i>Cancer</i> 83: 1626-1633. [1998] Prognostic Discrimination Among Neuroblastomas According to Ha-ras/irk A Gene Expression						
	4	Badner <i>et al.</i> , <i>Anesth. Analg.</i> 87: 711-713. [1998] The Use of Intraoperative Nitrous Oxide Leads to Postoperative Increases in Plasma Homocysteine						
	5							
	6							
	7							
	8							
	9							
	10							
	11							
	12							
	13							
	14							
	15							
	16							
	17							
	18							
Examiner: J. Goldberg				Date Considered: 3/18/04				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								



RECEIVED

APR 11 2001

Sheet 1 of 8

FORM PTO-1449
(Modified)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: H0501-0444 Serial: 2903,887

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: Kirk Hogan

Filing Date: July 11, 2000

Group Art Unit:

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

JS	(1)	Sweitzer B. (ed.), <i>Handbook of Preoperative Assessment and Management</i> , first edition, [2000], Lippincott, Williams and Wilkins, pgs 16-38						
	(2)	Erickson et al., <i>Anesthesia and Perioperative Complications</i> , second edition, [1999] pp. 741-751. Assessment of Anesthetic Risk						
	3	Baum et al., <i>Anesthesia for Genetic, Metabolic, and Dysmorphic Syndromes of Childhood</i> , first edition, [1999] Lippincott, Williams and Wilkins. This reference is a textbook and is not being supplied at this time but will be supplied at the Examiner's request.						
	4	Hardman et al., <i>Goodman & Gilman's The Pharmacological Basis of Therapeutics</i> , ninth edition, [1996], McGraw Hill. This reference is a textbook and is not being supplied at this time but will be supplied at the Examiner's request.						
JS	5	Bothner et al., Building a large scale perioperative anaesthesia outcome-tracking database: methodology, implementation, and experiences from one provider within the German quality project. <i>British Journal of Anaesthesia</i> 85(2): 271-80, 2000.						
	6	Douglas, Malignant hyperthermia persists though its profile changes. <i>Anesthesiology News</i> 25: 1 [1999]						
	7	Savarese et al., <i>Anesthesia</i> (RD, M., Ed.) pp 420, and 453, Churchill Livingstone, Philadelphia, PA. [2000]						
	8	Jacobs, <i>Progress in Anes</i> 7:39 [1998]. This reference is not being supplied at this time but will be supplied when available.						
JS	9	Schein et al., <i>NEJM</i> 342:168 [2000]						
	10	Roizen, <i>NEJM</i> 342:204 [2000]						
	11	Prows et al., Optimizing drug therapy based on genetic differences: implications for the clinical setting. <i>AACN Clinical Issues</i> 9(4), 499-512, 1998.						
	12	Kalow, <i>Pharmacological Reviews</i> 49:369 [1997] Pharmacogenetics in biological perspective.						
	13	Vesell, <i>Ann Int Med</i> 126:653 [1997] Therapeutic lessons from pharmacogenetics.						
	14	Ball et al., <i>Nature Biotechnology</i> 15:925 [1997] Pharmacogenetics and drug metabolism.						
	15	Evans et al., <i>Science</i> 286:487 [1999] Pharmacogenomics: translating functional genomics into rational therapeutics.						
	16	Nebert, <i>Clin Genet</i> 56: 247 [1999] Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?						
	17	Beaudet, <i>Am J Hum Genet</i> 64:1 [1999] 1998 ASHG presidential address.						
	18	Nebert, <i>Am J Hum Genet</i> 60:265 [1997] Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?						
	19	Daly, <i>J Mol Med</i> 73:539 [1995] Molecular basis of polymorphic drug metabolism.						
	20	Dale et al., <i>Acta Anaesthesiol Scand</i> 42:1025 [1998] Cytochrome P450, molecular biology and anaesthesia.						
	21	Meyer, <i>PNAS</i> 91:1983 [1994] Pharmacogenetics: the slow, the rapid, and the ultrarapid.						
	22	Brown et al., <i>Nature Genetics</i> 18:91 [1998] Genomics and human disease--variations on variation.						

Examiner:


J. Goldberg

Date Considered:

5/24/01

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: HOGAN-04448		Serial No.: 09/613,887	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Kirk Hogan			
				Filing Date: July 11, 2000		Group Art Unit:	
(37 CFR § 1.98(b))							
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)							
83	23	Marshall, <i>Nature Biotechnology</i> 15:954 [1997] Laying the foundations for personalized medicines					
	24	Time poll on genetic testing. [1999]					
	25	Licking, The Great Chip Derby. <i>Business Week</i> 10/25/99, 90, [1999]					
	26	Griffin <i>et al.</i> , <i>PNAS</i> , 96:6301 [1999] Direct genetic analysis by matrix-assisted laser desorption/ionization mass spectrometry					
	27	Yox, <i>Laboratory Medicine</i> 30: 456 [1999]					
	28	Gunderson <i>et al.</i> , <i>Genome Research</i> 8: 1142 [1998] Mutation detection by ligation to complete n-mer DNA arrays.					
	29	Harris <i>et al.</i> , <i>Nature Biotechnology</i> 18: 384 [2000] Injecting new ideas into microarray printing					
	30	Steemers <i>et al.</i> , <i>Nature Biotechnology</i> 18: 91 [2000] Screening unlabeled DNA targets with randomly ordered fiber-optic gene arrays.					
	31	Chen <i>et al.</i> , <i>Genome Research</i> 10: 549 [2000] A microsphere-based assay for multiplexed single nucleotide polymorphism analysis using single base chain extension.					
	32	Garvin <i>et al.</i> , <i>Nature Biotechnology</i> 18: 95 [2000] MALDI-TOF based mutation detection using tagged <i>in vitro</i> synthesized peptides.					
	33	Griffin <i>et al.</i> , <i>TIBTECH</i> 18: 77 [2000]					
	34	<i>Nature Genetics</i> 21:1 [1999]. "The Chipping Forecast". This reference is not being supplied at this time but will be supplied when available.					
	35	Fodor, <i>Science</i> 277: 393 [1997]					
	36	Gerhold <i>et al.</i> , DNA chips: promising toys have become powerful tools. <i>TIBS</i> 24: (May) [1999]					
	37	Blanchard <i>et al.</i> , <i>Nature Biotechnology</i> 17: 953 [1999] Cheap DNA arrays-it's not all smoke and mirrors.					
	38	Gilles <i>et al.</i> , <i>Nature Biotechnology</i> 17: 365 [1999] Single nucleotide polymorphic discrimination by an electronic dot blot assay on semiconductor microchips.					
	39	Sapolsky <i>et al.</i> , <i>Genetic Analysis</i> 14: 187 [1999] High-throughput polymorphism screening and genotyping with high-density oligonucleotide arrays					
	40	Drmanac <i>et al.</i> , <i>Nature Biotechnology</i> 16: 54 [1998] Accurate sequencing by hybridization for DNA diagnostics and individual genomics.					
	41	Cotton, <i>Genetic Analysis</i> 14: 165 [1999] Mutation detection by chemical cleavage					
	42	Schafer <i>et al.</i> , <i>Nature Biotechnology</i> 16:33 [1998] DNA variation and the future of human genetics.					
	43	Henke C. IVD Technology Magazine, <www.deviceink.com/ivd/archive/99/008.html> and <... archive/9i8/11/010.tml>, <... archive/99/01/008.html> [1998].					
	44	Ryan <i>et al.</i> , <i>Molecular Diagnosis</i> 4: 135 [1999] Non-PCR-dependent detection of the factor V Leiden mutation from genomic DNA using a homogeneous invader microtiter plate assay. This reference is not being supplied at this time but will be supplied when available.					
	83	45	Kaiser <i>et al.</i> , <i>J Biol Chem</i> 274: 21387 [1999] A comparison of eubacterial and archaeal structure-specific 5'-exonucleases.				
46	Oldenburg <i>et al.</i> , <i>BioTechniques</i> 28: 351 [2000] New Cleavase Fragment Length Polymorphism method improves the mutation detection assay.						
47	Andersen <i>et al.</i> , <i>Molecular Diagnosis</i> 3: 105 [1998] Mutation Detection by Cleavase in Combination With Capillary Electrophoresis Analysis: Application to Mutations Causing Hypertrrophic Cardiomyopathy and Long-QT Syndrome. This reference is not being supplied at this time but will be supplied when available.						
83	48	Mein <i>et al.</i> , <i>Genome Research</i> 10: 330 [2000] Evaluation					
49	Issaksson IA <i>et al.</i> , <i>Curr Opin Biotechnol</i> 10: 11 [1999]						
50	Vaughan <i>et al.</i> , <i>Genetic Analysis</i> 14: 169 [1999] Glycosylase mediated polymorphism detection (GMPD)-a novel process for genetic analysis.						
Examiner: J. Goldberg				Date Considered: 5/24/01			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

RECEIVED

APR 11 2001

TECH CENTER 1600/2900

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: HOGAN-04448

Serial No.: 09/613,887

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: Kirk Hogan

Filing Date: July 11, 2000

Group Art Unit:

(37 CFR § 1.98(b))

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

51	Graves, <i>Trends Biotechnol</i> 17: 127 [1999] Powerful tools for genetic analysis come of age.
52	Walt, <i>Science</i> 287:451 [2000] Techview: molecular biology. Bead-based fiber-optic arrays.
53	Persidis, <i>Hospital Practice</i> 11/15/99: 67 [1999] Biochips: an evolving clinical technology.
54	Taylor <i>et al.</i> , <i>Genetic Analysis</i> 14:181 [1999] Enzymatic methods for mutation scanning.
55	Cargill <i>et al.</i> , <i>Nature Genetics</i> 22:231 [1999] Characterization of single-nucleotide polymorphisms in coding regions of human genes.
56	Sleigh <i>et al.</i> , <i>Anaesth Intensive Care</i> 28: 54 [2000] Generic polymerase chain reaction followed by DNA sequencing as a means of diagnosing bacteraemia.
57	Halushka <i>et al.</i> , <i>Nature Genetics</i> 22: 239 [1999] Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis.
58	Kwok, <i>Clinical Chemistry</i> 46:593 [2000] Finding a needle in a haystack: detection and quantification of rare mutant alleles are coming of age.
59	Ravine, <i>J Inherited Metab Dis</i> 22:503 [1999] Automated Mutation analysis.
60	Hatch <i>et al.</i>, <i>Genet Anal</i> 15, 35-40. [1999] Rolling circle amplification of DNA immobilized on solid surfaces and its application to multiplex mutation detection. This reference is not being supplied at this time but will be supplied when available.
61	Chen <i>et al.</i> , <i>Genome Res</i> 8, 549-56. A homogeneous, ligase-mediated DNA diagnostic test.
62	Lizardi <i>et al.</i> , <i>Nat Genet</i> 19, 225-32. [1998] Mutation detection and single-molecule counting using isothermal rolling-circle amplification.
63	Nilsson <i>et al.</i> , <i>Nat Genet</i> 16, 252-5. [1997] Padlock probes reveal single-nucleotide differences, parent of origin and in situ distribution of centromeric sequences in human chromosomes 13 and 21.
64	Saiki <i>et al.</i> , <i>Science</i> 230, 1350-4. [1985] Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.
65	Stryer, <i>Annu Rev Biochem</i> 47, 819-46. [1978] Fluorescence energy transfer as a spectroscopic ruler. This reference is not being supplied at this time but will be supplied when available.
66	Cardullo <i>et al.</i> , <i>Proc Natl Acad Sci U S A</i> 85, 8790-4. [1988] Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer.
67	Ghosh <i>et al.</i> , <i>Nucleic Acids Res</i> 22, 3155-9. [1994] Real time kinetics of restriction endonuclease cleavage monitored by fluorescence resonance energy transfer.
68	Chee <i>et al.</i> , <i>Science</i> 274, 610-4. [1996] Accessing genetic information with high-density DNA arrays.
69	Shuber <i>et al.</i> , <i>Hum Mol Genet</i> 6, 337-47. [1997] High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes.
70	Holland <i>et al.</i> , <i>Proc Natl Acad Sci U S A</i> 88, 7276-80. [1991] Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of <i>Thermus aquaticus</i> DNA polymerase.
71	Pastinen <i>et al.</i> , <i>Genome Res</i> 7, 606-14. [1997] Minisequencing: a specific tool for DNA analysis and diagnostics on oligonucleotide arrays.
72	Wu <i>et al.</i> , <i>Proc Natl Acad Sci U S A</i> 86, 2757-60. [1989] Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia.
73	Landegren <i>et al.</i> , <i>Science</i> 241, 1077-80. [1988] A ligase-mediated gene detection technique.
74	Barany, <i>PCR Methods Appl</i> 1, 5-16. [1991] The ligase chain reaction in a PCR world.
75	Barany, <i>Proc Natl Acad Sci U S A</i> 88, 189-93. [1991] Genetic disease detection and DNA amplification using cloned thermostable ligase
76	Landegren, U <i>et al.</i> <i>Genome Res</i> 8, 769-76. [1998] Reading bits of genetic information: methods for single-nucleotide polymorphism analysis.

Examiner:

J. Goldberg

Date Considered:

5/24/01

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: HOGAN-04448

Serial No.: 09/613,887

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: Kirk Hogan

Filing Date: July 11, 2000

Group Art Unit:

APR 11 2001

(37 CFR § 1.98(b))

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

TECH CENTER 600,

77	Schena, M. et al. <i>W. Trends Biotechnol</i> 16, 301-6. [1998] Microarrays: biotechnology's discovery platform for functional genomics
78	Gilles, P. N. et al. <i>Nat Biotechnol</i> 17, 365-70. [1999] Single nucleotide polymorphic discrimination by an electronic dot blot assay on semiconductor microchips.
79	Tang, K. et al. <i>Proc Natl Acad Sci U S A</i> 96, 10016-20. [1999] Chip-based genotyping by mass spectrometry.
80	Singh-Gasson, S. et al. <i>Nat Biotechnol</i> 17, 974-8. [1999] Maskless fabrication of light-directed oligonucleotide microarrays using a digital micromirror array.
81	Cho, R. J. et al. <i>Nat Genet</i> 23, 203-7. [1999] Genome-wide mapping with biallelic markers in <i>Arabidopsis thaliana</i> .
82	Hacia, J. G. et al. <i>Nat Genet</i> 22, 164-7. [1999] Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays.
83	Wang, D. G. et al. <i>Science</i> 280, 1077-82. [1998] Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome.
84	Hacia, J. G. <i>Nat Genet</i> 21, 42-7. [1999] Resequencing and mutational analysis using oligonucleotide microarrays. This reference is not being supplied at this time but will be supplied when available.
85	Livak, K. et al. <i>PCR Methods Appl</i> 4, 357-62. [1995] Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.
86	Tyagi, S. et al. <i>Nat Biotechnol</i> 16, 49-53. [1998] Multicolor molecular beacons for allele discrimination.
87	Mutter, G. L. et al. <i>Nucleic Acids Res</i> 23, 1411-8. [1995] PCR bias in amplification of androgen receptor alleles, a trinucleotide repeat marker used in clonality studies.
88	Barnard, R. et al. <i>Biotechniques</i> 25, 684-91. [1998] CR bias toward the wild-type k-ras and p53 sequences: implications for PCR detection of mutations and cancer diagnosis.
89	Brookes, A. J. <i>Gene</i> 234, 177-86. [1999] The essence of SNPs
90	Lander, E. S. <i>Science</i> 274, 536-9. [1996] The new genomics: global views of biology.
91	Hall, J. et al. <i>Proc Natl Acad Sci U S A</i> 97, 8272-8277. [2000] From the cover: sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction.
92	Hessner, M. J. et al. <i>Clin Chem</i> 46, 1051-6. [2000] Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes.
93	Bedford, M. et al. <i>J Molec Diagnostics</i> 2, 97-104. [2000]. This reference is not being supplied at this time but will be supplied when available.
94	Nori, B. P. et al. in <i>Advances in Nucleic Acid and Protein Analysis</i> pp 117-125. [2000]. This reference is not being supplied at this time but will be supplied when available.
95	Hall, J., et al. <i>Hepatology</i> 28, 583A (abstract). [1998]
96	Vener, T. et al. in <i>15th Ann Clin Vir Symp, Clearwater Beach, FL</i> [1999]. This reference is not being supplied at this time but will be supplied when available.
97	Lyamichev, V. et al. <i>Nat Biotechnol</i> 17, 292-6. [1999] Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes.
98	Kwiatkowski, R. W. et al. <i>Mol Diagn</i> 4, 353-64. [1999] Clinical, genetic, and pharmacogenetic applications of the Invader assay.
99	Reynaldo, L. P. et al. <i>J Mol Biol</i> 297, 511-20. [2000] The kinetics of oligonucleotide replacements.
100	Lyamichev, V. I. et al. <i>Biochemistry</i> 39, 9523-32. [2000] Experimental and theoretical analysis of the invasive signal amplification reaction.
101	Lyamichev, V. et al. <i>Proc Natl Acad Sci U S A</i> 96, 6143-8. [1999] Comparison of the 5' nuclease activities of Taq DNA polymerase and its isolated nuclease domain.

Examiner:

J. Goldberg

Date Considered:


5/24/01

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: HOGAN-04448	Serial No.: 09/613,887
INFORMATION STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Kirk Hogan	
(37 CFR § 1.98(b))				Filing Date: July 11, 2000	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
82	102	Hacia <i>et al.</i> <i>J Med Genet</i> 36:730 [1999] Mutational analysis using oligonucleotide microarrays.			
	103	Greer LA. NEJM 342:242 [2000] The challenge of thrombophilia in maternal-fetal medicine. This reference is not being supplied at this time but will be supplied when available.			
83	104	Gerhardt A <i>et al.</i> <i>NEJM</i> 342:374 [2000] Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.			
	105	Watkins H. <i>NEJM</i> 342:422 [2000] Sudden death in hypertrophic cardiomyopathy.			
	106	Hillner B <i>Am J Hum Genet</i> 59:287 [1996] Genetic tests: a search for economy of scale.			
	107	Wald NJ <i>et al.</i> <i>BMJ</i> 319:1562 [1999] When can a risk factor be used as a worthwhile screening test?			
	108	Jurkat-Rott, K <i>et al.</i> <i>Nat Genet</i> 10, 111-3. [1995]			
	109	La Du, B. N., <i>et al.</i> <i>Cell Mol Neurobiol</i> 11, 79-89. [1991] Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing.			
	110	Kalow, W., and Grant, D. M. in <i>The metabolic and molecular bases of inherited disease</i> (Scriver, C. R., Stanbury, J. B., Wyngaarden, J. B., and Fredrickson, D. S., Eds.) pp 293-322, McGraw-Hill. [1993]. This reference is not being supplied at this time but will be supplied when available.			
	111	Sachse, C. <i>et al.</i> <i>N Engl J Med</i> 336, 399-403. [1997]. This reference is not being supplied at this time but will be supplied when available.			
84	112	De Stefano, V., <i>et al.</i> <i>N Engl J Med</i> 341, 801-6. [1999] The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.			
	113	Majetschak, M., <i>et al.</i> <i>Ann Surg</i> 230, 207-14. [1999]			
	114	Stuber, F. <i>et al.</i> (1996) <i>Crit Care Med</i> 24, 381-4. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. This reference is not being supplied at this time but will be supplied when available.			
85	115	Orkin, F., and Thomas, S. in <i>Anesthesia</i> (Miller, R., Ed.) pp 2579, Churchill Livingstone, Philadelphia, PA. [2000]			
	116	Sindrup, S. H. <i>et al.</i> <i>Clin Pharmacol Ther</i> 48, 686-93. [1990] Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.			
	117	Weisberg, I., <i>et al.</i> <i>Mol Genet Metab</i> 64, 169-72. [1998] A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.			
	118	Harmon, D. L. <i>et al.</i> <i>Genet Epidemiol</i> 17, 298-309. [1999] Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations.			
	119	Tsai, M. Y. <i>et al.</i> <i>Am J Hum Genet</i> 59, 1262-7. [1996] High prevalence of a mutation in the cystathionine beta-synthase gene.			
	120	Brandt, A., <i>et al.</i> <i>Hum Mol Genet</i> 8, 2055-62. [1999] Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test.			
	121	Monnier, N <i>et al.</i> <i>Am J Hum Genet</i> 60, 1316-25. [1997] Alignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.			
	122	Tarkowski, E <i>et al.</i> <i>Neurology</i> 54, 2077-81. [2000] TNF gene polymorphism and its relation to intracerebral production of TNFalpha and TNFbeta in AD.			
	123	Fleish, R. <i>et al.</i> <i>Cytokine</i> 11, 173-8. [1999] Relation of ex vivo stimulated blood cytokine synthesis to post-traumatic sepsis. This reference is not being supplied at this time but will be supplied when available.			
86	124	Mira, J. P. <i>et al.</i> <i>JAMA</i> 282, 561-8. [1999] Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study.			
	125	Freeman, R. B <i>et al.</i> <i>Transplantation</i> 67, 1005-10. [1999] Tumor necrosis factor genetic polymorphisms correlate with infections after liver transplantation. NEMC TNF Study Group. New England Medical Center Tumor Necrosis Factor.			
	126	Faioni, E. M., <i>et al.</i> <i>Blood</i> 94, 3062-6. [1999] Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden).			
Examiner:		J. Goldberg		Date Considered: 8/24/01	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: HOGAN-04448

Serial No.: 09/613,887

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: Kirk Hogan

Filing Date: July 11, 2000

Group Art Unit: APR 11 2001

(37 CFR § 1.98(b))

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

127	Singer <i>et al.</i> <i>BMJ</i> 319:501 [1999] ABC of intensive care. Cutting edge.
128	Schroeder S <i>et al.</i> <i>Crit Care Med</i> 27: 1265 [1999] Analysis of two human leukocyte antigen-linked polymorphic heat shock protein 70 genes in patients with severe sepsis.
129	Wang AM <i>et al.</i> <i>Science</i> 228:149 [1985] Molecular cloning of the complementary DNA for human tumor necrosis factor.
130	Masterson GR <i>et al.</i> <i>Br. J Anes</i> 77: 569 [1996] Does anaesthesia have long-term consequences?
131	Kumar A <i>et al.</i> <i>JAMA</i> 282:579 [1999] Genetic factors in septic shock.
132	Carlsson LE <i>et al.</i> <i>Blood</i> 92: 1526 [1998] Heparin-induced thrombocytopenia: new insights into the impact of the FcgammaRIIa-R-H131 polymorphism.
133	Rieder MJ <i>et al.</i> <i>Nature Genetics</i> 22:59 [1999] Sequence variation in the human angiotensin converting enzyme.
134	Vaccarino V <i>et al.</i> <i>Annals of Internal Medicine</i> 131:62 [1999] Risk factors for cardiovascular disease: one down, many more to evaluate.
135	Schuckit MA. <i>JAMA</i> 281:1875 [1999] New findings in the genetics of alcoholism.
136	Weiss EJ <i>et al.</i> <i>NEJM</i> 334:1090 [1996] A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
137	Goldschmidt-Clermont PJ. <i>et al.</i> <i>J Thromb and Thromb</i> 8:89 [1999] Platelet PIA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.
138	Heron E. <i>et al.</i> <i>Arch Intern Med</i> 160:382 [2000] Hypercoagulable states in primary upper-extremity deep vein thrombosis.
139	Gaughan G <i>et al.</i> <i>Genomics</i> 11:455 [1991] Refinement of the localization of human butyrylcholinesterase to chromosome 3q26.1-q26.2 using a PCR-derived probe.
140	LaDu B <i>Acta Anaesthesiol Scand</i> 39:139 [1995] Butyrylcholinesterase variants and the new methods of molecular biology.
141	Pantuck EJ <i>Anesth Analg</i> 77:380 [1993] Plasma cholinesterase: gene and variations.
142	Jensen FS <i>et al.</i> <i>Acta Anaesthesiol Scand</i> 39:151 [1995] Plasma cholinesterase and abnormal reaction to succinylcholine: twenty years' experience with the Danish Cholinesterase Research Unit.
143	Wood M <i>Anesthesiology</i> 71:631 [1989] Variability of human drug response
144	Johansson I <i>et al.</i> <i>PNAS</i> 90:11825 [1993] Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
145	Kroemer HK <i>et al.</i> <i>Life Sciences</i> 56:2285 [1995] "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.
146	Nguyen A <i>Mayo Clin Proc</i> 75:595 [2000] Prothrombin G20210A polymorphism and thrombophilia.
147	Poort SR <i>et al.</i> <i>Blood</i> 88:3698 [1996] A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.
148	Ridker PM <i>et al.</i> <i>Circulation</i> 99: 999 [1999] G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men.
149	Franco RF <i>et al.</i> <i>Br J Haematology</i> 104:50 [1999] The 20210 G-->A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease.
150	Griese EU <i>et al.</i> <i>Pharmacogenetics</i> 9:389 [1999] Detection of CYP2C19 alleles *1, *2 and *3 by multiplex polymerase chain reaction.
151	Morris P. <i>Pediatric Anesthesia</i> 7:1 [1999] Duchenne muscular dystrophy: a challenge for the anesthetist. This reference is not being supplied at this time but will be supplied when available.
152	McNicholl JM <i>et al.</i> <i>Am J Prev Med</i> 16:141 [1999] Host genes and infectious diseases. HIV, other pathogens, and a public health perspective.

Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: HOGAN-04448	Serial No.: 09/613,887
		Applicant: Kirk Hogan	
		Filing Date: July 11, 2000	Group Art Unit: APR 11 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

84	153	Ulevitch RJ <i>Nature</i> 401:755 [1999] Toll gates for pathogen selection.
	154	Muzio M <i>et al.</i> <i>J Exp Med</i> 187:2097 [1998] The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6).
	155	Sleigh JW <i>Anaesth Int Care</i> 28:53 [2000]
	156	Hillier CEM. <i>et al.</i> <i>Q J Med</i> 91:677 [1998] Inherited prothrombotic risk factors and cerebral venous thrombosis.
	157	Bick RL <i>et al.</i> (eds.) <i>Sem in Thromb and Hemostasis</i> 25:251 [1999] Hereditary and acquired thrombophilia. Part I. Preface.
	158	Stratton MA <i>et al.</i> <i>Arch Int Med</i> 160:334 [2000] Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients.
	159	Ginsberg JS <i>et al.</i> <i>Arch Int Med</i> 160:669 [2000] Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study.
	160	Tardiff BE <i>et al.</i> <i>Ann Thorac Surg</i> 64:715 [1997] Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center.
	161	Spiess BD <i>et al.</i> <i>J Cardiothoracic and Vascular Anesthesia</i> 14:2 [2000] Overview of myocardial outcome: the interrelationships among coagulation, inflammation, and endothelium.
	162	Tam YK <i>Clin Pharmacokinet</i> 25:300 [1993] Individual variation in first-pass metabolism.
	163	Nielsen GW <i>et al.</i> <i>J Int Med</i> 239:119 [1996] Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. This reference is not being supplied at this time but will be supplied when available.
	164	Pastinen T <i>et al.</i> <i>Hum Mol Gen</i> 7:1453 [1998] Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. This reference is not being supplied at this time but will be supplied when available.
85	165	Drazen JM <i>et al.</i> <i>Nature Genetics</i> 22: 168 [1999] Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.
	166	Ortega RA <i>et al.</i> <i>Am J Anesth</i> Nov:429 [1999]
	167	Berkowitz DE <i>et al.</i> <i>J Cardiothoracic and Vasc Anesth</i> 13:744 [1999] Molecular biology in cardiovascular anesthesiology: the brave new frontier.
	168	Ciccone GK <i>et al.</i> <i>Br J Anaesth</i> 82:255 [1999] Drugs and sex differences: a review of drugs relating to anaesthesia
	169	Martin G <i>et al.</i> <i>Sem in Anes, Periop Med and Pain</i> 19: 76 [2000]
	170	Geelen JLM <i>Eur Heart J</i> 19:1427 [1998] Molecular genetics of inherited long QT syndromes.
	171	Priori S <i>et al.</i> <i>Circulation</i> 99:529 [1999] Low penetrance in the long-QT syndrome: clinical impact.
	172	Berthlet M <i>et al.</i> <i>Circulation</i> 99:1464 [1999] C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence.
	173	Busjahn A. <i>et al.</i> <i>Circulation</i> 99:3161 [1999] QT interval is linked to 2 long-QT syndrome loci in normal subjects
	174	Priori S <i>et al.</i> <i>Circulation</i> 99:674 [1999] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III.
	175	Pleym H <i>et al.</i> <i>Acta Anaesth Scand</i> 43:352 [1999] Ventricular fibrillation related to reversal of the neuromuscular blockade in a patient with long QT syndrome.
	176	Priori S <i>et al.</i> <i>Circulation</i> 99:518 [1999] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II.
	177	Graham RM <i>et al.</i> <i>NEJM</i> 341: 1759 [1999] Pathogenesis of inherited forms of dilated cardiomyopathy.
	178	Fananapazir L <i>JAMA</i> 281:1746 [1999] Advances in molecular genetics and management of hypertrophic cardiomyopathy.

Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: HOGAN-04448	Serial No.: 09/613,887
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))				Applicant: Kirk Hogan	
				Filing Date: July 11, 2000	Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
179	Bonne G <i>et al.</i>	Circ Res 83:580 [1998] Familial hypertrophic cardiomyopathy: from mutations to functional defects			
180	Fuller BP <i>et al.</i>	Science 285:1359 [1999] Privacy in genetics research			
181	Coughlin SS	Am J Prev Med 16:89 [1999] The intersection of genetics, public health, and preventive medicine.			
182	Reid MC <i>et al.</i>	JAMA 274:645 [1995] Use of methodological standards in diagnostic test research. Getting better but still not good			
183	Holtzman NA	Science 286:409 [1999] Are genetic tests adequately regulated?			
184	McGovern MM. <i>et al.</i>	JAMA 281:835 [1999] Quality assurance in molecular genetic testing laboratories.			
185	Grody <i>et al.</i>	JAMA 281:845 [1999] Report card on molecular genetic testing: room for improvement?			
186	O'Donnell <i>et al.</i>	NEJM 342:240-245 [2000] Apolipoprotein E Genotype And The Risk Of Recurrent Labor Intracerebral Hemorrhage			
187	Caplan,	Anesthesia and Perioperative Complications, second edition, [1999], pp. 760-770, The Cost of Adverse Outcome			
188	Posner <i>et al.</i>	Anesthesia and Perioperative Complications, second edition, [1999], pp. 752-759, Current Spectrum Of Anesthetic Injury.			
189	Lander,	Nature Genetics [1999] 21:3-4, Array of Hope			
190	Southern <i>et al.</i>	Nature Genetics [1999] 21:5-8, Molecular Interactions on Microarrays			
191	Duggan <i>et al.</i>	Nature Genetics [1999] 21:10-14, Expression profiling using cDNA microarrays			
192	Cheung <i>et al.</i>	Nature Genetics [1999] 21:15-19, Making and reading microarrays			
193	Lipshutz <i>et al.</i>	Nature Genetics [1999] 21:20-24, High density synthetic oligonucleotide arrays			
194	Bowtell,	Nature Genetics [1999] 21:25-32, Options available - from start to finish - for obtaining expression data by microarray			
195	Brown <i>et al.</i>	Nature Genetics [1999] 21:33-37, Exploring the new world of the genome with DNA microarrays			
196	Cole <i>et al.</i>	Nature Genetics [1999] 21:38-41, The genetics of cancer - a 3D model			
197	Debouck <i>et al.</i>	Nature Genetics [1999] 21:48-50, DNA microarrays in drug discovery and development			
198	Bassett <i>et al.</i>	Nature Genetics [1999] 21:51-55, Gene expression informatics it's all in your mine			
199	Chakravarti,	Nature Genetics [1999] 21:56-60, Population genetics - making sense out of sequence			
200	The Blue Sheet, October 13, 1999				
201	Pharmacogenetics, Chapter 4, pp. 303-309				
202	Pharmacogenetics, Chapter 4, pp. 309-326				
203	Samioti <i>et al.</i>, N. Engl. J. Med [1997] 336:399-405, The risk of recurrent venous thromboembolism in patients with an Arg⁵⁰⁶→Gln mutation in the gene for factor V (factor V Leiden). This reference is not being supplied at this time but will be supplied when available.				
204	Lindmarker <i>et al.</i>, Thromb Haemost [1999] 81:684-9, The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1601A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. This reference is not being supplied at this time but will be supplied when available.				
205	Le Royer <i>et al.</i>, Thromb Haemost [1998] Prevalence of the 20210 A allele of the prothrombin gene in venous thromboembolism patients. This reference is not being supplied at this time but will be supplied when available.				
206	Margaglione <i>et al.</i>, Ann Intern Med [1998] 129:89-95 increased risk for venous thrombosis in carriers of the prothrombin G → A²⁰²¹⁰ gene variant. This reference is not being supplied at this time but will be supplied when available.				
Examiner: <i>g. Goldberg</i>		Date Considered: <i>5/24/01</i>			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: HOGAN-04448	Serial No.: 09/613,887	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Kirk Hogan		
(37 CFR § 1.98(b))				Filing Date: July 11, 2000		Group Art Unit:

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
	1	4,683,195	07/28/87	Mullis <i>et al.</i>	435	6	02/07/86
	2	4,683,202	07/28/87	Mullis	435	91	10/25/85
	3	4,965,188	10/23/90	Mullis <i>et al.</i>	435	6	06/17/87
	4	5,843,654	12/02/98	Heisler <i>et al.</i>	435	6	06/07/95
	5	5,843,669	12/01/98	Kaiser <i>et al.</i>	356	6	11/29/96
	6	5,719,028	02/17/98	Dahlberg <i>et al.</i>	435	6	02/06/97
	7	5,888,780	03/30/99	Dahlberg <i>et al.</i>	435	91.53	02/19/97
	8	6,045,996	04/04/00	Cronin <i>et al.</i>	435	6	05/16/96
	9	5,925,525	07/20/99	Fodor <i>et al.</i>	435	6	04/03/98
	10	5,858,659	01/12/99	Sapolsky <i>et al.</i>	435	6	11/29/95
	11	6,017,696	01/25/00	Heller	435	6	07/07/94
	12	6,068,818	05/30/00	Ackley <i>et al.</i>	422	50	01/29/99
	13	6,051,380	04/18/00	Sosnowski <i>et al.</i>	435	6	12/05/97
	14	6,001,311	12/14/99	Brennan	422	131	02/05/97
	15	5,985,551	11/15/99	Brennan	435	6	06/06/95
	16	5,474,796	12/12/95	Brennan	427	2.13	05/27/93
	17	5,846,717	12/08/98	Brow <i>et al.</i>	435	6	01/24/96
	18	6,001,567	12/14/99	Brow <i>et al.</i>	435	6	07/12/96
	19	5,985,557	11/16/99	Prudent <i>et al.</i>	435	6	11/26/96
	20	5,994,069	11/30/99	Hall <i>et al.</i>	435	6	03/24/97
	21	5,538,848	07/23/96	Livak <i>et al.</i>	435	5	11/16/94
	22	5,952,174	09/14/99	Nikiforov <i>et al.</i>	435	6	09/15/97
	23	5,919,626	07/06/99	Shi <i>et al.</i>	435	6	06/06/97
	24	6,043,031	03/28/00	Koster <i>et al.</i>	435	6	03/18/96
	25	5,777,324	07/07/98	Hillenkamp	250	288	09/19/96
	26	5,605,798	02/25/97	Koster	435	6	03/17/95

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS								
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	27	WO 99/67641	12/29/99	PCT				
	28	WO 00/39587	07/06/00	PCT				
	29	WO 99/64626		PCT				
	30	WO 99/64627		PCT				

Examiner: <u>J. Goldberg</u>	Date Considered: <u>5/24/01</u>
------------------------------	---------------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: HOGAN-04448	Serial No.: 09/613,887	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Kirk Hogan		
				Filing Date: July 11, 2000	Group Art Unit:	
(37 CFR § 1.98(b))						
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)						
<div style="position: relative; height: 100%; border-left: 1px solid black; margin-left: 10px;"> <div style="position: absolute; top: 0; left: -20px;">84</div> <div style="position: absolute; bottom: 0; left: -20px;">85</div> <div style="position: absolute; bottom: 0; left: -20px;">86</div> </div>	31	Pedersen, Dan Med Bull., 41:319 [1994]. We are unable to locate this reference and we are providing the Abstract. If the Examiner requests the entire reference it will be provided.				
	32	Liang and Cullen, Anesthesiology, 91: 609 [1999];				
	33	Wolff, New Eng. J. Med., 324:486-488 [1991];				
	34	Mira, JAMA 282:561-568 [1999];				
	35	Anderson and Young, Quantitative Filter Hybridization, in <i>Nucleic Acid Research</i> [1985];				
	36	Kacian <i>et al.</i> , Proc. Natl. Acad. Sci. USA, 69:3038 [1972];				
	37	Chamberlin <i>et al.</i> , Nature, 228:227 [1970]				
	38	Wu and Wallace, Genomics, 4:560 [1989]				
	39	H.A. Erlich (ed.), <i>PCR Technology</i> , Stockton Press [1989];				
	40	Sambrook <i>et al.</i> , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY, pp 9.31-9.58 [1989]				
	41	Graham and Van Der Eb, Virol., 52:456 [1973];				
	42	La Du <i>et al.</i> , Cell. and Molec. Neurobiol., 11:79 [1991];				
	43	Vladutiu <i>et al.</i> , Am J. Hum. Genet., 29:A5 [1998];				
	44	Monnier <i>et al.</i> , Am. J. Hum. Genet., 60:1316 [1997];				
	45	Priori <i>et al.</i> , Circulation, 99:518 [1999];				
	46	Brick, Seminars in Thrombosis and Hemostasis, 25:251 [1999];				
	47	Frosst <i>et al.</i> , Nature Genet., 10:111 [1995];				
	48	Harmon <i>et al.</i> , Genet. Epidemiol., 17:298 [1999];				
	49	Simoni <i>et al.</i> , New Eng. J. Med., 336:399 [1997];				
	50	Yamamoto <i>et al.</i> , Nature, 345:229 [1990];				
	51	Ausabel <i>et al.</i> (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY [1991]. This reference is not being supplied at this time but if the Examiner requests the reference it will be submitted.				
	52	Kwiatkowski <i>et al.</i>, Molecular Diagnosis, 4:363 [1999]. This reference is not being supplied at this time but if the Examiner requests the reference it will be submitted.				
	53	R.D. Miller, (ed.), Anesthesia, fifth edition, Churchill Livingstone, [2000], pgs. 824-883. This reference is not being supplied at this time but will be supplied at a later time.				
	54	Genostic Pharma Recieves Two Gene Profiling Patents," Genetic Engineering News, 20:61 [2000]				
	55	Pembrook, "To Reduce Pre-Op Tests, Inform Surgeons of Their Practices," Anesthesiology News, June, [1999];				
	56	Mlessides, "Anesthesiologists at Increased Risk for Latex Sensitization," Anesthesiology News, December, [1999]. This reference is not being supplied at this time but will be supplied at a later time.				
	57	Pembrook, "Pre-Op Tests in ambulatory anesthesia must be patient driven," Anesthesiology News, June, [1999]. This reference is not being supplied at this time but will be supplied at a later time.				
	58	Pembrook, "Anesthesia Technique, Patients medical history often not related," Anesthesiology News, June, [1999];				
	59	Pembrook, "Pre-Op consults often do not affect management or outcome," Anesthesiology News, June, [1999];				
	60	Koitabashi <i>et al.</i> , "Identification of a Genetic Defect Responsible for the Polymorphism of Propofol Metabolism: Poor Metabolism of 2C19 in Two Patients," Anesth. Analg. Abstracts, 88:S1-424 [1999];				
	61	Klaschik <i>et al.</i> , Crit Care Med., 27:A138 [1999]				
	62	Risch, "Searching for Genetic Determinants in the New Millennium," Nature, 405:847 [2000].				
	Examiner: <i>J. Goldberg</i>		Date Considered: <i>5/24/01</i>			
	EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: HOGAN-04448		Serial No.: 09/613,887	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))				Applicant: Kirk Hogan			
				Filing Date: July 11, 2000		Group Art Unit:	
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)							
	1	Nature Genetics 21:1 [1999]. "The Chipping Forecast".					
	2	Ryan et al., Molecular Diagnosis 4: 135 [1999] Non-PCR-dependent detection of the factor V Leiden mutation from genomic DNA using a homogeneous invader microtiter plate assay.					
	3	Andersen et al., Molecular Diagnosis 3: 105 [1998] Mutation Detection by Cleavase in Combination With Capillary Electrophoresis Analysis: Application to Mutations Causing Hypertrophic Cardiomyopathy and Long-QT Syndrome.					
	4	Hatch et al., Genet Anal 15, 35-40. [1999] Rolling circle amplification of DNA immobilized on solid surfaces and its application to multiplex mutation detection.					
	5	Stryer, Annu Rev Biochem 47, 819-46. [1978] Fluorescence energy transfer as a spectroscopic ruler.					
	6	Hacia, J. G. Nat Genet 21, 42-7. [1999] Resequencing and mutational analysis using oligonucleotide microarrays.					
	7	Ledford, M. et al. J Molec Diagnostics 2, 97-104. [2000].					
	8	Neri, B. P. et al. in Advances in Nucleic Acid and Protein Analysis pp 117-125. [2000].					
	9	Greer IA. NEJM 342:242 [2000] The challenge of thrombophilia in maternal-fetal medicine.					
	10	Kalow, W., and Grant, D. M. in The metabolic and molecular bases of inherited disease (Scriver, C. R., Stanbury, J. B., Wyngaarden, J. B., and Fredrickson, D. S., Eds.) pp 293-322, McGraw-Hill. [1995].					
	11	Stuber, F. et al. (1996) Crit Care Med 24, 381-4. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis.					
	12	Flach, R. et al. Cytokine 11, 173-8. [1999] Relation of ex vivo stimulated blood cytokine synthesis to post-traumatic sepsis.					
	13	Nielsen EW et al. J Int Med 239:119 [1996] Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses.					
	14	Pastinen T et al. Hum Mol Gen 7:1453 [1998] Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population.					
	15	Simioni et al. N. Engl. J. Med [1997] 336:399-403, The risk of recurrent venous thromboembolism in patients with an Arg ⁵⁰⁶ →Gln mutation in the gene for factor V (factor V Leiden).					
	16	Lindmarker et al., Thromb Haemost [1999] 81:684-9, The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene.					
	17	Leroyer et al., Thromb Haemost [1998] Prevalence of the 2021- A allele of the prothrombin gene in venous thromboembolism patients.					
	18	Margaglione et al., Ann Intern Med [1998] 129:89-93 Increased risk for venous thrombosis in carriers of the prothrombin G → A ²⁰²¹⁰ gene variant.					
Examiner: <i>J. Goldberg</i>				Date Considered: <i>5/24/01</i>			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

RECEIVED

MAY 02 2001

TECH CENTER 1600/2901